Insilico's founder and CEO, Alex Zhavoronkov, stated that the company's AI platform can find connections between clinical trial success or failure, disease conditions, and drug attributes that might elude human scientists. The company has been training inClinico on clinical trials, drugs, and diseases since 2014, enhancing its predictive capabilities. The company projects that approximately 20 to 25% of trials can be predictably assessed using the inClinico tool with meaningful accuracy.
Key takeaways:
- Insilico Medicine, a clinical-stage AI drug discovery company, has successfully predicted Phase II to Phase III clinical trial outcomes using its proprietary generative transformer-based AI tool, inClinico.
- The AI platform demonstrated a 79% accuracy rate when validated against real-world trials, and its accurate predictions resulted in a 35% return on investment over 9 months in a virtual trading portfolio.
- The AI tool incorporates various engines that harness the power of gen AI and multimodal data, including text, omics, clinical trial design, and small molecule properties, and its training data includes more than 55,600 unique Phase II clinical trials from the past seven years.
- Insilico's CEO, Alex Zhavoronkov, believes that the system’s sophistication and precision will continuously improve over time, driven by a surge in data and reinforcement, including insights from Insilico’s internal pipeline programs.